You are using an outdated browser. Please upgrade your browser to improve your experience and security.

VYXEOS is a fixed course of therapy that allows patients time off sAML treatment1,a,b

Administer first consolidation cycle 5 to 8 weeks after the start of the last induction1

The majority of patients received induction with VYXEOS in an inpatient setting during the Phase 3 trial2

51% of patients received consolidation with VYXEOS in an outpatient setting during the Phase 3 trial3

Learn the patient factors to consider for outpatient administration with VYXEOS

Second induction (if needed)1

Daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 liposome on Days 1 and 3

  • In patients not achieving a response, start 2 to 5 weeks after first induction

Second consolidation (if needed)1

Daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 liposome on Days 1 and 3

  • 5 to 8 weeks after the start of first consolidation in patients who do not show disease progression or unacceptable toxicity

Dosing considerations

  • Prior to initiating each cycle, calculate the prior cumulative anthracycline exposure for the patient1
  • Assess cardiac function, complete blood counts, and liver and renal function before each consolidation cycle1
  • Do not start consolidation until the absolute neutrophil count (ANC) recovers to greater than 0.5 Gi/L and the platelet count recovers to greater than 50 Gi/L in the absence of unacceptable toxicity1

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.